Sectors
IBRX
ImmunityBio, Inc.
7.65
1 x 7.58
1 x 7.68
bid
ask
-
0.09
1.16%
3 @ 04:00 PM
7.66 +0.01 (0.15%)
| Ytd | 286.36% | |
| 1y | 171.28% |
7.59
day range
7.96
1.95
52 week range
12.43
| Open | 7.79 | Prev Close | 7.74 | Low | 7.59 | High | 7.96 | Mkt Cap | 8.01B |
| Vol | 5.95M | Avg Vol | 12.12M | EPS | -0.97 | P/E | -7.89 | Forward P/E | -60.39 |
| Beta | 0.13 | Short Ratio | 12.85 | Inst. Own | 18.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 7.63 | 200-d Avg | 6.11 | 1yr Est | 12.75 |
| Income Statement | |||
| Total Revenue | 51.24M | ||
| Revenues (USD) | 51.24M | ||
| Cost of Revenue | 298.00K | ||
| Gross Profit | 50.94M | ||
| Operating Expenses | 112.64M | ||
| Research and Development Expense | 60.82M | ||
| Selling, General and Administrative Expense | 51.82M | ||
| Operating Income | -61.70M | ||
| Interest Expense | 31.24M | ||
| Net Income | -230.38M | ||
| Net Income Common Stock | -230.38M | ||
| Net Income Common Stock (USD) | -230.38M | ||
| Consolidated Income | -230.39M | ||
| Net Income to Non-Controlling Interests | -12.00K | ||
| Earnings per Basic Share | -0.22 | ||
| Earnings per Basic Share (USD) | -0.22 | ||
| Earnings per Diluted Share | -0.22 | ||
| Earning Before Interest & Taxes (EBIT) | -199.13M | ||
| Earning Before Interest & Taxes (USD) | -199.13M | ||
| Weighted Average Shares | 1.05B | ||
| Weighted Average Shares Diluted | 1.05B | ||
| Balance Sheet | |||
| Cash and Equivalents | 75.67M | ||
| Cash and Equivalents (USD) | 75.67M | ||
| Investments | 281.70M | ||
| Investments Current | 281.70M | ||
| Trade and Non-Trade Receivables | 53.50M | ||
| Current Assets | 438.98M | ||
| Property, Plant & Equipment Net | 145.49M | ||
| Total Assets | 628.50M | ||
| Debt Current | 7.51M | ||
| Total Debt | 1.23B | ||
| Current Liabilities | 76.73M | ||
| Debt Non-Current | 1.22B | ||
| Total Liabilities | 1.67B | ||
| Accumulated Retained Earnings (Deficit) | -4.59B | ||
| Accumulated Other Comprehensive Income | 27.28M | ||
| Shareholders Equity | -1.05B | ||
| Shareholders Equity (USD) | -1.05B | ||
| Assets Non-Current | 189.52M | ||
| Total Debt (USD) | 1.23B | ||
| Goodwill and Intangible Assets | 11.84M | ||
| Inventory | 18.36M | ||
| Liabilities Non-Current | 1.60B | ||
| Trade and Non-Trade Payables | 13.55M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 6.17M | ||
| Net Cash Flow from Financing | 44.44M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -129.52M | ||
| Capital Expenditure | -3.54M | ||
| Issuance (Purchase) of Equity Shares | 45.40M | ||
| Issuance (Repayment) of Debt Securities | -898.00K | ||
| Net Cash Flow from Investing | -107.47M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -103.93M | ||
| Net Cash Flow from Operations | -66.49M | ||
| Effect of Exchange Rate Changes on Cash | -3.00K | ||
| Share Based Compensation | 8.52M | ||